Abbott Laboratories (ABT) Stock Forecast: What Could Drive It in 2026
Short answer
What is actually driving Abbott Laboratories (ABT) right now is FreeStyle Libre: A Platform, Not Just a Product: FreeStyle Libre exceeded $7.5 billion in 2025 annual sales and grew roughly 19-20% organically in H1 2025, making it the dominant revenue engine within Medical Devices. Revenue (TTM) is ~$45.1 billion. If that keeps playing out, the setup is favourable; the risk to it is the most acute near-term risk is infant formula litigation: juries have delivered verdicts including a $53 million compensatory award in late March 2026 and a separately upheld $495 million verdict, with hundreds of additional NEC-related cases still pending, and a securities class action filed in 2026 adds a parallel legal exposure track targeting alleged investor misstatements. No one can predict where ABT trades, and Walnut does not publish targets, so treat this as a scenario, not a price target or prediction.
What could drive Abbott Laboratories (ABT) higher?
FreeStyle Libre: A Platform, Not Just a Product
FreeStyle Libre exceeded $7.5 billion in 2025 annual sales and grew roughly 19-20% organically in H1 2025, making it the dominant revenue engine within Medical Devices. The platform is expanding into over-the-counter wellness use cases via Lingo and Libre Rio, broadening the addressable market well beyond Type 1 and Type 2 diabetes management. Abbott recently secured a CE Mark for the world's first dual glucose-ketone sensing technology, pointing to further clinical differentiation.
Cardiovascular and Electrophysiology Momentum
The cardiovascular and electrophysiology portfolio, including Navitor, TriClip, Amplatzer Amulet, and the AVEIR leadless pacemaker, delivered double-digit organic growth in H1 2025, with structural heart growing roughly 13% organically. Recent FDA approvals broaden the addressable patient population and position Abbott to close the gap on category leaders Medtronic and Boston Scientific. The division benefits from durable procedure-volume tailwinds driven by an aging global population.
Cancer Diagnostics Expansion via Exact Sciences
The approximately $21 billion acquisition of Exact Sciences, closed in early 2026, adds the Cologuard non-invasive colorectal cancer screening test and a liquid biopsy pipeline to Abbott's diagnostics portfolio, addressing a roughly $60 billion oncology diagnostics market opportunity. Combined with Abbott's existing Alinity laboratory platform and global commercial infrastructure, the deal is designed to accelerate multi-cancer early detection capabilities. Management has guided for full-year 2026 comparable sales growth of 6.5-7.5%, including contributions from Exact Sciences.
Dividend Durability and Capital Return
Abbott has raised its dividend for more than 53 consecutive years, with the quarterly payment increased to $0.63 per share in January 2026, representing a 6.8% increase from the prior rate and implying an annualized payout of $2.52 per share. Free cash flow consistently covers dividends with a payout ratio near 60-67%, leaving capacity for buybacks and tuck-in M&A. The company's Altman Z-Score places it firmly in the low-bankruptcy-risk zone, and its balance sheet has supported large acquisitions while maintaining a manageable debt-to-EBITDA profile.
What could weigh on ABT?
The most acute near-term risk is infant formula litigation: juries have delivered verdicts including a $53 million compensatory award in late March 2026 and a separately upheld $495 million verdict, with hundreds of additional NEC-related cases still pending, and a securities class action filed in 2026 adds a parallel legal exposure track targeting alleged investor misstatements. Integration of the approximately $21 billion Exact Sciences acquisition introduces execution risk, short-term EPS dilution, and elevated SGA costs that compressed Q1 2026 operating earnings year over year. Foreign exchange headwinds have consistently shaved 2-3 percentage points off reported international revenue growth, and any meaningful dollar strengthening would pressure reported results disproportionately given Abbott's broad non-US exposure. Competitive disruption in continuous glucose monitoring from DexCom and emerging players, along with pricing pressure from government payers and the Inflation Reduction Act, represent structural long-term headwinds.
How to think about a ABT forecast
Rather than chasing a price target, it tends to help to weigh the drivers above against the risks, decide how long you are willing to hold, and size the position so a wrong call is survivable. A “forecast” is really a probability-weighted view of those drivers playing out, not a number.
For the full picture, see the ABT guide and whether ABT is a buy. In Walnut you can pressure-test the thesis against your real portfolio.
The bottom line on the ABT outlook
The bottom line: what is driving Abbott Laboratories (ABT) is FreeStyle Libre: A Platform, Not Just a Product, with revenue (ttm) at ~$45.1 billion. If that keeps playing out the setup is favourable; the risk is the most acute near-term risk is infant formula litigation: juries have delivered verdicts including a $53 million compensatory award in late March 2026 and a separately upheld $495 million verdict, with hundreds of additional NEC-related cases still pending, and a securities class action filed in 2026 adds a parallel legal exposure track targeting alleged investor misstatements. No one can predict the price, so treat any ABT forecast as a scenario, not a target or prediction, and decide from your own thesis and time horizon. Walnut is not an investment adviser.
Build a basket around ABT with Walnut
Use Abbott Laboratories as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What is the forecast for Abbott Laboratories (ABT)?
+
No one can reliably predict where ABT will trade, and Walnut does not publish price targets. What is more useful is the setup: the drivers that could push Abbott Laboratories higher and the risks that could weigh on it. This page lays out both so you can form your own view. Not a recommendation.
What could drive ABT higher?
+
The main growth drivers are FreeStyle Libre: A Platform, Not Just a Product; Cardiovascular and Electrophysiology Momentum; Cancer Diagnostics Expansion via Exact Sciences. Whether they play out is the real question, not a guaranteed path.
What are the risks to ABT?
+
The most acute near-term risk is infant formula litigation: juries have delivered verdicts including a $53 million compensatory award in late March 2026 and a separately upheld $495 million verdict, with hundreds of additional NEC-related cases still pending, and a securities class action filed in 2026 adds a parallel legal exposure track targeting alleged investor misstatements. Integration of the approximately $21 billion Exact Sciences acquisition introduces execution risk, short-term EPS dilution, and elevated SGA costs that compressed Q1 2026 operating earnings year over year. Foreign exchange headwinds have consistently shaved 2-3 percentage points off reported international revenue growth, and any meaningful dollar strengthening would pressure reported results disproportionately given Abbott's broad non-US exposure. Competitive disruption in continuous glucose monitoring from DexCom and emerging players, along with pricing pressure from government payers and the Inflation Reduction Act, represent structural long-term headwinds.
Will ABT stock go up in 2026?
+
Nobody knows, and anyone who says they do is guessing. Abbott Laboratories's direction depends on whether the drivers above outweigh the risks, plus the broader market. Focus on the thesis and your time horizon rather than a single-year call.
Is ABT a buy?
+
That depends on your thesis, time horizon, and what you already own, not on a forecast. See the ABT "is it a buy?" page for a framework. Walnut is not an investment adviser.
Walnut is informational, not investment advice. This page describes drivers and risks; it is not a price forecast, target, or recommendation. Markets are uncertain and past performance does not predict future results.